LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L)
Authors: Hickish, T., Tseng, L.-M., Mehta, A.O., Tsang, J., Kovalenko, N., Udovitsa, D., Pelling, K., Uttenreuther-Fischer, M.M. and Huang, C.-S.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Volume: 30
Issue: 15
eISSN: 1527-7755
ISSN: 0732-183X
Source: Web of Science (Lite)
Preferred by: Tamas Hickish